EMA Begins Review Of Phase I Trial Guideline Based On French Inquiry Findings
This article was originally published in SRA
Executive Summary
The European Medicines Agency has begun reviewing its guideline on first-in-human (FIH) trials following the tragic events in France in January this year when the Phase I study with Bial's FAAH inhibitor BIA 10-2474 led to the death of one volunteer and the hospitalization of five others1.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.